Loss of the promyelocytic leukemia protein in gastric cancer: Implications for IP-10 expression and tumor-infiltrating lymphocytes

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Kim, Hee Ja ^a   Song, Dong Eun ^b   Lim, Seul Ye ^a   Lee, Sung Hee ^a   Kang, Jihee Lee ^a   Lee, Sun Jung ^c   Benveniste, Etty N ^d   Choi, Youn Hee ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA; PROMYELOCYTIC LEUKEMIA PROTEIN; STAT1 PROTEIN; CYTOKINE RECEPTOR; DNA; IP10 MIG RECEPTOR; IP10-MIG RECEPTOR; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANIMAL CELL; ARTICLE; CANCER TISSUE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IP 10 GENE; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; SUPERNATANT; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL MOTION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN BINDING; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, CYTOKINE; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 80053942865     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026264     Document Type: Article

References (55)

1. Kyrlagkitsis I, Karamanolis DG, (2004) Genes and gastric cancer. Hepatogastroenterology 51: 320-327.
2. Lee HE, Jee CD, Kim MA, Lee HS, Lee YM, et al. (2007) Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett 247: 103-109.
3. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, et al. (2004) Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96: 269-279.
4. Borrow J, Goddard AD, Sheer D, Solomon E, (1990) Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249: 1577-1580.
5. de The H, Lavau C, Marchio A, Chomienne C, Degos L, et al. (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675-684.
6. Goddard AD, Borrow J, Freemont PS, Solomon E, (1991) Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371-1374.
7. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, et al. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66: 663-674.
8. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, et al. (1991) Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6: 1285-1292.
9. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, et al. (1998) Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551.
10. LaMorte VJ, Dyck JA, Ochs RL, Evans RM, (1998) Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci U S A 95: 4991-4996.
11. Wu WS, Xu ZX, Ran R, Meng F, Chang KS, (2002) Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions. Oncogene 21: 3925-3933.
12. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, et al. (2001) Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 7: 1233-1243.
13. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, et al. (2001) The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259-2268.
14. Vallian S, Gaken JA, Gingold EB, Kouzarides T, Chang KS, et al. (1998) Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene 16: 2843-2853.
15. Cairo S, De Falco F, Pizzo M, Salomoni P, Pandolfi PP, et al. (2005) PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts. Oncogene 24: 2195-2203.
16. Guo A, Salomoni P, Luo J, Shih A, Zhong S, et al. (2000) The function of PML in p53-dependent apoptosis. Nat Cell Biol 2: 730-736.
17. Choi YH, Bernardi R, Pandolfi PP, Benveniste EN, (2006) The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci U S A 103: 18715-18720.
18. Tamura G, (2006) Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 12: 192-198.
19. de Visser KE, Coussens LM, (2006) The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13: 118-137.
20. Lorusso G, Ruegg C, (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091-1103.
21. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA, (2004) The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108: 173-180.
22. Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, et al. (2007) Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 604: 67-86.
23. Balkwill F, Mantovani A, (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
24. Balkwill F, Charles KA, Mantovani A, (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
25. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
26. Karin M, Lawrence T, Nizet V, (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835.
27. Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, et al. (2007) Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 178: 5552-5562.
28. Bingle L, Brown NJ, Lewis CE, (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
29. Maltby S, Khazaie K, McNagny KM, (2009) Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796: 19-26.
30. Takanami I, Takeuchi K, Naruke M, (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88: 2686-2692.
31. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
32. Vazquez-Cintron EJ, Monu NR, Frey AB, (2010) Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol 185: 7133-7140.
33. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, et al. (2003) CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94: 1003-1009.
34. Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, et al. (2010) Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 23: 1393-1403.
35. O'Hayre M, Salanga CL, Handel TM, Allen SJ, (2008) Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409: 635-649.
36. Ben-Baruch A, (2006) The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 25: 357-371.
37. Lee EY, Lee ZH, Song YW, (2009) CXCL10 and autoimmune diseases. Autoimmun Rev 8: 379-383.
38. Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, et al. (1995) Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11: 2565-2573.
39. Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, et al. (2009) IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog 5: e1000369.
40. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud O, (2006) T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 55: 830-840.
41. Neville LF, Mathiak G, Bagasra O, (1997) The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8: 207-219.
42. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, et al. (2003) Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 74: 360-369.
43. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, et al. (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132-5136.
44. Zhang P, Chin W, Chow LT, Chan AS, Yim AP, et al. (2000) Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 85: 599-605.
45. Bollrath J, Greten FR, (2009) IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10: 1314-1319.
46. Naugler WE, Karin M, (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14: 109-119.
47. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856.
48. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
49. Ancrile B, Lim KH, Counter CM, (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719.
50. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102.
51. Kawasaki A, Matsumura I, Kataoka Y, Takigawa E, Nakajima K, et al. (2003) Opposing effects of PML and PML/RAR alpha on STAT3 activity. Blood 101: 3668-3673.
52. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, et al. (2003) Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem 278: 12294-12304.
53. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, et al. (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6: 665-672.
54. Fruman DA, Pai SY, Burakoff SJ, Bierer BE, (1995) Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells. Mol Cell Biol 15: 3857-3863.
55. Ohmori Y, Hamilton TA, (1993) Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J Biol Chem 268: 6677-6688.